Boosting a Natural Brain Cannabinoid Blocked Opioid Reward Without Reducing Pain Relief
Elevating the endocannabinoid 2-AG in mice substantially reduced the rewarding effects of opioids while preserving their pain-relieving properties.
Quick Facts
What This Study Found
Pharmacologically boosting 2-AG levels via MAGL inhibition attenuated opioid reward in both conditioned place preference and self-administration paradigms without affecting opioid analgesia. The effect was mediated by CB1 receptors in the VTA. Enhancing anandamide had no effect.
Key Numbers
MAGL inhibition with JZL184 attenuated opioid reward in both CPP and self-administration. VTA CB1R knockout reversed effects. FAAH inhibition (anandamide) had no effect.
How They Did This
Animal study using male and female mice. Opioid reward assessed by CPP and self-administration. CB1 receptor involvement confirmed with VTA-specific conditional knockout. Fiber photometry measured nucleus accumbens activity and dopamine transmission.
Why This Research Matters
The opioid crisis demands alternatives that provide pain relief without addiction potential. Targeting 2-AG could allow opioids to work for pain while stripping away their rewarding properties.
The Bigger Picture
If these findings translate to humans, 2-AG-boosting drugs could be co-prescribed with opioids for pain management, potentially reducing addiction risk while maintaining therapeutic benefit.
What This Study Doesn't Tell Us
Mouse model may not predict human pharmacology. Long-term effects of chronic MAGL inhibition not addressed. Controlled lab settings may not reflect complex clinical scenarios.
Questions This Raises
- ?Would MAGL inhibitors reduce opioid misuse in humans?
- ?Why does 2-AG but not anandamide modulate opioid reward?
Trust & Context
- Key Stat:
- 2-AG elevation blocked opioid reward via VTA CB1 receptors while fully preserving analgesia
- Evidence Grade:
- Well-designed animal study with multiple paradigms and mechanistic confirmation, but no human data.
- Study Age:
- Published as a 2024 preprint on bioRxiv.
- Original Title:
- Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.
- Published In:
- bioRxiv : the preprint server for biology (2024)
- Authors:
- Martínez-Rivera, Arlene, Fetcho, Robert N, Birmingham, Lizzie, Jiu, Jin X, Yang, Ruirong, Foord, Careen, Scala-Chávez, Diego, Mekawy, Narmin, Pleil, Kristen, Pickel, Virginia M, Liston, Conor, Castorena, Carlos M, Levitz, Joshua, Pan, Ying-Xian, Briand, Lisa A, Rajadhyaksha, Anjali M, Lee, Francis S
- Database ID:
- RTHC-05521
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can you make opioids less addictive?
In mice, boosting 2-AG reduced opioid reward without reducing pain relief, suggesting a possible strategy.
Does the endocannabinoid system affect opioid addiction?
2-AG acts through CB1 receptors in the brain's reward center to dampen opioid reward and reduce dopamine signaling.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05521APA
Martínez-Rivera, Arlene; Fetcho, Robert N; Birmingham, Lizzie; Jiu, Jin X; Yang, Ruirong; Foord, Careen; Scala-Chávez, Diego; Mekawy, Narmin; Pleil, Kristen; Pickel, Virginia M; Liston, Conor; Castorena, Carlos M; Levitz, Joshua; Pan, Ying-Xian; Briand, Lisa A; Rajadhyaksha, Anjali M; Lee, Francis S. (2024). Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.04.02.585967
MLA
Martínez-Rivera, Arlene, et al. "Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.." bioRxiv : the preprint server for biology, 2024. https://doi.org/10.1101/2024.04.02.585967
RethinkTHC
RethinkTHC Research Database. "Elevating levels of the endocannabinoid 2-arachidonoylglycer..." RTHC-05521. Retrieved from https://rethinkthc.com/research/martinez-rivera-2024-elevating-levels-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.